Organon reports Q4 adjusted EPS 81c, consensus 90c

Reports Q4 revenue $1.49B, consensus $1.51B. "We enter 2023 with momentum, building off the significant achievements in our short history as an independent company," said Kevin Ali, Organon’s CEO. "Since these products have been in our hands, we have set three quarterly sales records for Nexplanon, delivered two consecutive years of double-digit revenue growth in Biosimilars and demonstrated the durability of the Established Brands franchise. We have also continued to position the company for future growth with active business development – adding seven assets in Women’s Health and a second partner in Biosimilars. We remain committed to continuing to deliver on the promise of our portfolio and advancing the innovation needed to improve women’s health."